Antimicrobial Resistance and Infection Control

Antimicrobial Resistance and Infection Control is an open access journal published by BMC, launched in 2012, devoted to preventing healthcare-associated infections and antimicrobial resistance, with a 2025 Journal Impact Factor of 5.2.《抗微生物耐药性与感染控制》（Antimicrobial Resistance and Infection Control）是（BMC）出版的开放获取期刊，2012 年创刊，专注医疗相关感染与抗微生物耐药性的预防，2025 年影响因子 5.2。

Scope

• Healthcare epidemiology and infection prevention and control across hospitals and other care settings are the journal's core.医疗流行病学以及医院与其他照护环境中的感染预防与控制，是本刊的核心。
• Antimicrobial resistance surveillance and stewardship are considered where they relate directly to prevention.与预防直接相关的耐药监测与抗菌药物管理在考虑之列。
• Outbreak investigation, hand hygiene, environmental cleaning and device-associated infection are central topics.暴发调查、手卫生、环境清洁与器械相关感染是核心议题。
• Surveillance networks and multicentre epidemiological analyses, with evaluation of control interventions, are welcomed.监测网络与多中心流行病学分析，以及对防控干预的评估，均受到欢迎。
• Research from low-, middle- and high-income countries is sought, with an emphasis on findings that travel.刊物面向低、中、高收入国家征集研究，重视可迁移的结论。
• One Health and public health submissions are accepted when they bear directly on human resistance or on healthcare-associated infection.公共卫生与“同一健康”视角的来稿，须与人类耐药或医疗相关感染直接相关方可受理。
• The journal does not routinely consider single-centre resistance estimates, clinical diagnosis and treatment, or laboratory genomics with no infection-prevention implication.本刊通常不受理单中心耐药率估计、传染病临床诊治，以及缺乏感染预防含义的实验室基因组研究。

History

• The journal was founded in 2012 by BMC, and volume 1 appeared in the same year.本刊由（BMC）于 2012 年创办，第 1 卷同年问世。
• Its founding editors were Didier Pittet, Christina Vandenbroucke-Grauls and Andreas Voss, who stepped down in 2017.创刊主编为 Didier Pittet、Christina Vandenbroucke-Grauls 与 Andreas Voss，三人于 2017 年卸任。
• Publication is continuous, with one volume a year, reaching volume 15 in 2026.刊物采用连续出版方式，每年一卷，2026 年为第 15 卷。
• It works in partnership with the International Consortium for Prevention and Infection Control, the Infection Control Africa Network and the Asia Pacific Society of Infection Control.本刊与感染预防与控制国际联盟（ICPIC）、非洲感染控制网络以及亚太感染控制学会保持学会合作关系。
• Conference abstract supplements have appeared since 2013, from the second ICPIC meeting to the eighth in 2025.自 2013 年第二届 ICPIC 会议起持续出版会议摘要增刊，至 2025 年第八届。
• The Journal Impact Factor was 4.887 in 2021, 6.454 in 2022, 4.4 in 2024 and 5.2 in 2025, with a five-year value of 5.7.影响因子 2021 年为 4.887，2022 年为 6.454，2024 年为 4.4，2025 年为 5.2，五年影响因子为 5.7。
• The publisher reports a median of 12 days from submission to first decision and 2.3 million downloads in 2025.出版方公布，投稿至首次决定的中位时间为 12 天，2025 年下载量达 230 万次。

Editors

• Three editors-in-chief lead the journal: Ermira Tartari of the University of Malta, Sarah Tschudin-Sutter of the University Hospital of Basel and Andrew Whitelaw of Stellenbosch University.本刊设三位主编：马耳他大学（University of Malta）的 Ermira Tartari、巴塞尔大学医院（University Hospital of Basel）的 Sarah Tschudin-Sutter，以及斯泰伦博斯大学（Stellenbosch University）的 Andrew Whitelaw。
• Roughly twenty-five associate editors cover Europe, Africa, Asia, the Americas and Australia.约 25 位副编辑覆盖欧洲、非洲、亚洲、美洲与大洋洲。
• Review is single-anonymous, so reviewers see author names and affiliations while reports reaching authors are anonymised, and at least two experts normally assess each paper.评审采用单匿名制，评审人知晓作者姓名与单位，返回作者的评审意见则匿名，每篇通常由至少两位专家评审。
• Authors may suggest or ask to exclude reviewers in the cover letter, giving institutional email addresses or ORCID identifiers for verification.作者可在投稿信中建议或请求回避评审人，建议时须提供机构邮箱或 ORCID 等可核验信息。
• The board is being expanded, with open calls for associate editors and a reviewer board for early-career infection prevention researchers.编委会正在扩容，公开招募副编辑，并设立面向早期职业感染预防研究者的评审人委员会。
• Editors screen submissions against the stated exclusions, so single-centre resistance surveys and treatment studies are usually returned without review.编辑按公开的排除条款初筛稿件，单中心耐药调查与治疗类研究通常不经外审即退回。